Curative high-dose reirradiation for patients with recurrent head and neck squamous cell carcinoma using IMRT or proton therapy: Outcomes and analysis of patterns of failure

Head Neck. 2022 Nov;44(11):2452-2464. doi: 10.1002/hed.27153. Epub 2022 Jul 25.

Abstract

Purpose: To analyze outcomes of patients treated with curative reirradiation (reRT), with intensity-modulated radiation therapy (IMRT) or proton therapy (PT) for recurrent head and neck squamous cell carcinoma (HNSCC).

Materials: Among the 55 patients reirradiated for head and neck cancer from 30/08/2012 to 08/04/2019, 23 had HNSCC and received IMRT (52.2%) or PT (47.8%) at a median maximum dose to the CTV of 66 Gy.

Results: After a median follow-up of 41.3 months, 18 patients developed a locoregional recurrence (LR), of which eight (44.4%) occurred within the previously reirradiated volume. Two-year locoregional failure-free survival and overall survival were 18.3%[95%CI:7.1%-47.1%] and 42.5%[95%CI:26.2%-69.1%], respectively. Disease-free survival was significantly longer in the PT group (p = 0.031). Main late grade ≥2 toxicities were dysphagia and trismus.

Conclusion: Curative reRT in HNSCC is possible for selected cases, but the LR rate in the irradiated field and the risk of toxicity grade ≥2 remain high.

Keywords: IMRT; Reirradiation; head and neck carcinoma; proton therapy; toxicity.

MeSH terms

  • Carcinoma, Squamous Cell*
  • Head and Neck Neoplasms* / etiology
  • Head and Neck Neoplasms* / radiotherapy
  • Humans
  • Neoplasm Recurrence, Local
  • Proton Therapy* / adverse effects
  • Radiotherapy Dosage
  • Radiotherapy, Intensity-Modulated* / adverse effects
  • Re-Irradiation* / adverse effects
  • Squamous Cell Carcinoma of Head and Neck / etiology
  • Squamous Cell Carcinoma of Head and Neck / radiotherapy